Discover the promising results of a recent trial that investigated the use of MMA embolisation for treating non-acute subdural haematomas. Learn about the benefits, success rate, and potential patient populations that may benefit from this innovative treatment approach.
| Outcome Measure | MMA Embolisation Group | Control Group |
|---|---|---|
| Primary Endpoint-related Outcomes at 90 days | 7.2% | 12.2% |
| All-cause Mortality at 90 days | 0.6% | 2.2% |
The MAGIC-MT trial has shown that MMA embolisation alongside standard care is superior to standard care alone in the treatment of non-acute subdural haematomas. The procedure resulted in fewer haematoma recurrence/progression and lower mortality rates at 90 days. Subgroup analyses also indicated a larger treatment effect in certain patient populations. Further clinical trials are needed to confirm these findings and establish MMA embolisation as a standard treatment option.
MMA Embolisation: A Promising Treatment for Non-Acute Subdural Haematomas
A recent randomised controlled trial (RCT) called MAGIC-MT has found that the use of middle meningeal artery (MMA) embolisation alongside standard care is superior to standard care alone for patients with symptomatic, non-acute subdural haematomas (SDHs). The trial, presented at the International Stroke Conference, showed that MMA embolisation resulted in less haematoma recurrence/progression and lower mortality at 90 days.
The multicentre trial enrolled 727 patients with non-acute SDH and randomised them to receive either MMA embolisation with the Onyx liquid embolic system or standard care alone. The primary endpoint of the trial was the rate of death, symptomatic SDH recurrence, or progression within 90 days. The secondary endpoints included various clinical, radiographical, and health-economic outcomes.
The results of the trial demonstrated a significant reduction in primary endpoint-related outcomes in the MMA embolisation group compared to the control group. The MMA embolisation procedure also had an extremely high success rate of 98.3% and a low rate of complications. Subgroup analyses further indicated a larger treatment effect with MMA embolisation in certain patient populations.
While these findings are promising, further clinical trials are needed to confirm the efficacy of MMA embolisation in the treatment of non-acute SDHs. Nevertheless, this study provides valuable insights into a potential new approach for managing this condition.
